Exchanges of genomic domains between poliovirus and other cocirculating species C enteroviruses reveal a high degree of plasticity

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Bessaud, Maël ^a,b   Joffret, Marie Line ^a,b   Blondel, Bruno ^a,b   Delpeyroux, Francis ^a,b  

^a INSTITUT PASTEUR   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ENTEROVIRUS C; GENETIC RECOMBINATION; GENETICS; HUMAN; PHENOTYPE; POLIOMYELITIS VIRUS; TUMOR CELL LINE; VIRUS GENOME; VIRUS REPLICATION;

CELL LINE, TUMOR; ENTEROVIRUS C, HUMAN; GENOME, VIRAL; HUMANS; PHENOTYPE; POLIOVIRUS; RECOMBINATION, GENETIC; VIRUS REPLICATION;

EID: 85006059646     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep38831     Document Type: Article

References (60)

1. Koike, S. & Nomoto, A. Poliomyelitis In The Picornaviruses (eds Ehrenfeld, E., Domingo, E. & Roos, R. P.) 339-351 (ASM Press, 2010).
2. Paul, A. V. & Wimmer, E. Initiation of protein-primed picornavirus RNA synthesis. Virus research, doi: 10.1016/j. virusres.2014.12.028 (2015).
3. Zoll, J., Heus, H. A., van Kuppeveld, F. J. & Melchers, W. J. The structure-function relationship of the enterovirus 3′-UTR. Virus Res 139, 209-216, doi: 10.1016/j.virusres.2008.07.014 (2009).
4. Vogt, D. A. & Andino, R. An RNA element at the 5′-end of the poliovirus genome functions as a general promoter for RNA synthesis. PLoS pathogens 6, e1000936, doi: 10.1371/journal.ppat.1000936 (2010).
5. Minor, P. D., Macadam, A. J., Stone, D. M. & Almond, J. W. Genetic basis of attenuation of the Sabin oral poliovirus vaccines. Biologicals 21, 357-363, doi: 10.1006/biol.1993.1096 (1993).
6. Minor, P. D. The molecular biology of poliovaccines. J Gen Virol 73 (Pt 12), 3065-3077, doi: 10.1099/0022-1317-73-12-3065 (1992).
7. De Jesus, N. H. Epidemics to eradication: the modern history of poliomyelitis. Virol J 4, 70, doi: 10.1186/1743-422X-4-70 (2007).
8. Combelas, N., Holmblat, B., Joffret, M. L., Colbere-Garapin, F. & Delpeyroux, F. Recombination between poliovirus and coxsackie A viruses of species C: a model of viral genetic plasticity and emergence. Viruses 3, 1460-1484, doi: 10.3390/v3081460 (2011).
9. Kew, O. M., Sutter, R. W., de Gourville, E. M., Dowdle, W. R. & Pallansch, M. A. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 59, 587-635, doi: 10.1146/annurev.micro.58.030603.123625 (2005).
10. Burns, C. C., Diop, O. M., Sutter, R. W. & Kew, O. M. Vaccine-derived polioviruses. J Infect Dis 210 Suppl 1, S283-293, doi: 10.1093/infdis/jiu295 (2014).
11. Diop, O. M., Burns, C. C., Sutter, R. W., Wassilak, S. G. & Kew, O. M. Update on Vaccine-Derived Polioviruses-Worldwide, January 2014-March 2015. Mmwr-Morbid Mortal W 64, 640-646 (2015).
12. Morales, M., Nnadi, C. D., Tangermann, R. H. & Wassilak, S. G. Notes from the Field: Circulating Vaccine-Derived Poliovirus Outbreaks-Five Countries, 2014-2015. MMWR Morb Mortal Wkly Rep 65, 128-129, doi: 10.15585/mmwr.mm6505a5 (2016).
13. Dedepsidis, E., Kyriakopoulou, Z., Pliaka, V. & Markoulatos, P. Correlation between recombination junctions and RNA secondary structure elements in poliovirus Sabin strains. Virus Genes 41, 181-191, doi: 10.1007/s11262-010-0512-5 (2010).
14. Kew, O. et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 296, 356-359, doi: 10.1126/science.1068284 (2002).
15. Rakoto-Andrianarivelo, M. et al. Co-circulation and evolution of polioviruses and species C enteroviruses in a district of Madagascar. PLoS Pathog 3, e191, doi: 10.1371/journal.ppat.0030191 (2007).
16. Shimizu, H. et al. Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001. J Virol 78, 13512-13521, doi: 10.1128/JVI.78.24.13512-13521.2004 (2004).
17. Joffret, M. L. et al. Common and Diverse Features of Cocirculating Type 2 and 3 Recombinant Vaccine-Derived Polioviruses Isolated From Patients With Poliomyelitis and Healthy Children. J Infect Dis 205, 1363-1373, doi: 10.1093/infdis/jis204 (2012).
18. Adu, F. et al. Isolation of recombinant type 2 vaccine-derived poliovirus (VDPV) from a Nigerian child. Virus Res 127, 17-25, doi: 10.1016/j.virusres.2007.03.009 (2007).
19. Burns, C. C. et al. Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria. J Virol 87, 4907-4922, doi: 10.1128/JVI.02954-12 (2013).
20. Rakoto-Andrianarivelo, M. et al. Reemergence of recombinant vaccine-derived poliovirus outbreak in Madagascar. J Infect Dis 197, 1427-1435, doi: 10.1086/587694 (2008).
21. Yang, C. F. et al. Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993. J Virol 77, 8366-8377 (2003).
22. Bessaud, M., Joffret, M. L., Holmblat, B., Razafindratsimandresy, R. & Delpeyroux, F. Genetic relationship between cocirculating Human enteroviruses species C. PLoS One 6, e24823, doi: 10.1371/journal.pone.0024823 (2011).
23. Holmblat, B. et al. Nonhomologous recombination between defective poliovirus and coxsackievirus genomes suggests a new model of genetic plasticity for picornaviruses. MBio 5, e01119-01114, doi: 10.1128/mBio.01119-14 (2014).
24. Muslin, C., Joffret, M. L., Pelletier, I., Blondel, B. & Delpeyroux, F. Evolution and Emergence of Enteroviruses through Intra-and Inter-species Recombination: Plasticity and Phenotypic Impact of Modular Genetic Exchanges in the 5′ Untranslated Region. PLoS Pathog 11, e1005266, doi: 10.1371/journal.ppat.1005266 (2015).
25. Riquet, F. B. et al. Impact of exogenous sequences on the characteristics of an epidemic type 2 recombinant vaccine-derived poliovirus. J Virol 82, 8927-8932, doi: 10.1128/JVI.00239-08 (2008).
26. Jegouic, S. et al. Recombination between polioviruses and co-circulating Coxsackie A viruses: role in the emergence of pathogenic vaccine-derived polioviruses. PLoS Pathog 5, e1000412, doi: 10.1371/journal.ppat.1000412 (2009).
27. Shulman, L. M. et al. Molecular and antigenic characterization of a highly evolved derivative of the type 2 oral poliovaccine strain isolated from sewage in Israel. J Clin Microbiol 38, 3729-3734 (2000).
28. Anonymous. In Polio laboratory manual (ed. WHO) 39-72 (World Health Organization, 2004).
29. Bessaud, M. & Delpeyroux, F. Development of a simple and rapid protocol for the production of customized intertypic recombinant polioviruses. J Virol Methods 186, 104-108, doi: 10.1016/j.jviromet.2012.08.001 (2012).
30. Monpoeho, S. et al. Quantification of enterovirus RNA in sludge samples using single tube real-time RT-PCR. Biotechniques 29, 88-93 (2000).
31. Matrosovich, M., Matrosovich, T., Garten, W. & Klenk, H. D. New low-viscosity overlay medium for viral plaque assays. Virol J 3, 63, doi: 10.1186/1743-422X-3-63 (2006).
32. Horie, H. et al. Transgenic mice carrying the human poliovirus receptor: new animal models for study of poliovirus neurovirulence. J Virol 68, 681-688 (1994).
33. Kaplan, E. L. & Meier, P. Nonparametric estimation from incomplete observations. J Amer Statist Assn 53, 457-481 (1958).
34. R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, Vienna, Austria, 2015).
35. Reed, L. J. & Muench, M. A simple method for estimating fifty percent endpoints. Amer J Hyg 27, 493-497 (1938).
36. Therneau, T. & Grambsch, P. Modeling Survival Data: Extending the Cox Model. (Springer, 2000).
37. Macadam, A. J. et al. Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates. Virology 192, 18-26, doi: 10.1006/viro.1993.1003 (1993).
38. Evans, D. M. et al. Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome. Nature 314, 548-550 (1985).
39. Xiao, Y. H. et al. RNA Recombination Enhances Adaptability and Is Required for Virus Spread and Virulence. Cell Host & Microbe 19, 493-503, doi: 10.1016/j.chom.2016.03.009 (2016).
40. Jiang, P. et al. Evidence for emergence of diverse polioviruses from C-cluster coxsackie A viruses and implications for global poliovirus eradication. Proceedings of the National Academy of Sciences of the United States of America 104, 9457-9462, doi: 10.1073/pnas.0700451104 (2007).
41. Echeverri, A., Banerjee, R. & Dasgupta, A. Amino-terminal region of poliovirus 2C protein is sufficient for membrane binding. Virus Res 54, 217-223 (1998).
42. Wang, C. L., Jiang, P., Sand, C., Paul, A. V. & Wimmer, E. Alanine Scanning of Poliovirus 2C(ATPase) Reveals New Genetic Evidence that Capsid Protein/2C(ATPase) Interactions Are Essential for Morphogenesis. Journal of Virology 86, 9964-9975, doi: 10.1128/JVI.00914-12 (2012).
43. Wang, C. L., Ma, H. C., Wimmer, E., Jiang, P. & Paul, A. V. A C-terminal, cysteine-rich site in poliovirus 2C(ATPase) is required for morphogenesis. Journal of General Virology 95, 1255-1265, doi: 10.1099/vir.0.062497-0 (2014).
44. Horaud, F., Crainic, R. & Blondel, B. Polio vaccine: From empiricism and efficacy to scientific knowledge. Ann Inst Pasteur/Virol 136E, 527-545 (1985).
45. Sabin, A. B. & Lwoff, A. Relation between reproductive capacity of polioviruses at different temperatures in tissue culture and neurovirulence. Science 129, 1287-1288 (1958).
46. Gallet, R., Kannoly, S. & Wang, I. N. Effects of bacteriophage traits on plaque formation. BMC Microbiol 11, 181, doi: 10.1186/1471-2180-11-181 (2011).
47. Georgescu, M. M., Delpeyroux, F. & Crainic, R. Tripartite genome organization of a natural type 2 vaccine/nonvaccine recombinant poliovirus. J Gen Virol 76 (Pt 9), 2343-2348 (1995).
48. Ren, R. B., Moss, E. G. & Racaniello, V. R. Identification of two determinants that attenuate vaccine-related type 2 poliovirus. J Virol 65, 1377-1382 (1991).
49. Yan, D. et al. Limited and localized outbreak of newly emergent type 2 vaccine-derived poliovirus in Sichuan, China. Clin Vaccine Immunol 21, 1012-1018, doi: 10.1128/CVI.00196-14 (2014).
50. Zhang, Y. et al. Type 2 vaccine-derived poliovirus from patients with acute flaccid paralysis in china: current immunization strategy effectively prevented its sustained transmission. J Infect Dis 202, 1780-1788, doi: 10.1086/657410 (2010).
51. Kawamura, N. et al. Determinants in the 5′ noncoding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype. J Virol 63, 1302-1309 (1989).
52. Racaniello, V. R. One hundred years of poliovirus pathogenesis. Virology 344, 9-16, doi: 10.1016/j.virol.2005.09.015 (2006).
53. Knowlson, S. et al. New Strains Intended for the Production of Inactivated Polio Vaccine at Low-Containment After Eradication. PLoS Pathog 11, e1005316, doi: 10.1371/journal.ppat.1005316 (2015).
54. Agol, V. I. et al. Neurovirulence of the intertypic poliovirus recombinant v3/a1-25: characterization of strains isolated from the spinal cord of diseased monkeys and evaluation of the contribution of the 3′ half of the genome. J Gen Virol 66 (Pt 2), 309-316 (1985).
55. Agol, V. I. et al. Recombinants between attenuated and virulent strains of poliovirus type 1: derivation and characterization of recombinants with centrally located crossover points. Virology 143, 467-477 (1985).
56. Merkle, I. et al. Biological significance of a human enterovirus B-specific RNA element in the 3′ nontranslated region. J Virol 76, 9900-9909 (2002).
57. Vignuzzi, M., Stone, J. K., Arnold, J. J., Cameron, C. E. & Andino, R. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 439, 344-348, doi: 10.1038/nature04388 (2006).
58. Vignuzzi, M., Wendt, E. & Andino, R. Engineering attenuated virus vaccines by controlling replication fidelity. Nat Med 14, 154-161, doi: 10.1038/nm1726 (2008).
59. Pfeiffer, J. K. & Kirkegaard, K. Increased fidelity reduces poliovirus fitness and virulence under selective pressure in mice. PLoS Pathog 1, e11, doi: 10.1371/journal.ppat.0010011 (2005).
60. Beck, A. et al. Comparison of the live attenuated yellow fever vaccine 17D-204 strain to its virulent parental strain Asibi by deep sequencing. The Journal of infectious diseases 209, 334-344, doi: 10.1093/infdis/jit546 (2014).